NEDD4 family E3 ubiquitin ligases regulate cell signaling and trafficking events in 2 eukaryotic cells and their dysregulation is often observed in various human diseases. One 3 NEDD4 family member, WWP1, has been reported to undergo genomic amplification in breast 4 and prostate cancer yet its function in cancer progression is unclear. Proteomic analysis in 5 breast cancer cells revealed physical association of WWP1 with the deubiquitylase USP9X and 6 the WNT signaling protein DVL2. We report that USP9X is required for canonical WNT 7 activation in a WWP1-and NEDD4L-dependent manner. Our findings indicate that USP9X 8 regulates WNT activation via deubiquitylation of DVL2 and the ubiquitylation-deubiquitylation 9 cycle of DVL2 biases its participation in either canonical WNT or WNT-PCP pathways. The 10 finding of a WWP1/NEDD4L-USP9X regulatory axis that specifies DVL2 participation in 11 canonical and non-canonical WNT signaling pathways has important implications for therapeutic 12 targeting of USP9X in human cancer. 13
TABLE S3, and FIG 5A). These experiments revealed two near-stoichiometric interactions with 17
the AP-2 clathrin adaptor complex and with VANGL1 and cofilin which are important factors 18 known to participate in the non-canonical WNT PCP pathway (Luga et al., 2012) . Additionally, 19
we identified several sub-stoichiometric interactions with NEDD4 family E3 Ub ligases and 20 proteasome subunits (TABLE S2, TABLE S3 , and FIG 5A) . Many of these interactions had 21 been previously reported (Angers et al., 2006; Yu et al., 2007) . Several interactions were 22 confirmed by co-IP (FIG 5B and data not shown) and co-localization by immunofluorescence 23 microscopy (FIG 5C and data not shown). Consistent with previous reports (Yu et al., 2007; Yuet al., 2010) we also found that knockdown of AP-2 complex subunits inhibited canonical WNT 1 activation in a TOPFLASH assay (data not shown). 2
To quantify how DVL2 interactions are affected by ubiquitylation, we performed SILAC-MS 3 proteomic analysis comparing the interactome of catalytic active (light) or catalytic dead (heavy) 4 DUB-DVL2 fusions (also used in FIG 4A) . This revealed that the catalytic dead DUB-DVL2 5 fusion (which can be stably ubiquitylated) interacts more with proteasome subunits and 6 VANGL1/cofilin while the catalytic active DUB-DVL2 fusion (which is not stably ubiquitylated) 7 interacts more with the AP-2 complex (FIG 5D) . We also used SILAC-MS to quantify how DVL2 8 interactions are altered in usp9x knockout cells and found similar results: DVL2 interacted more 9 with VANGL1 and cofilin in usp9x knockout cells (where DVL2 ubiquitylation is elevated) but 10 interacted more with AP-2 in the presence of USP9X (where DVL2 is less ubiquitylated) (FIG  11   5E) . These results indicate ubiquitylated DVL2 interacts more with VANGL1/cofilin -12 components of the WNT-PCP pathway -while deubiquitylated DVL2 interacts more with the 13 AP-2 complex, which is critical for canonical WNT activation. 14
USP9X regulates cellular distribution of DVL2 15
Previous studies have reported that VANGL1 and cofilin localize to F-actin rich 16 projections in migrating MDA-MB-231 cells (Hatakeyama et al., 2014) . Based on our findings 17 that loss of USP9X results in increased ubiquitylation of DVL2 and increased interactions 18 between DVL2 and VANGL1/cofilin we hypothesized that loss of USP9X may result in re-19 localization of DVL2 to projections in MDA-MB-231 cells. To test this we used 20 immunofluorescence microscopy to characterize FLAG-Dvl2 distribution in MDA-MB-231 cells in 21 the presence or absence of USP9X. In MDA-MB-231 cells treated with control siRNAs, DVL2 22 exhibited a punctate distribution throughout the cell body, reflective of previous descriptions of 23 DVL2 localization (FIG 6A, left panel) (Schwarz-Romond et al., 2005) whereas MDA-MB-231cells treated with siRNAs targeting USP9X knockdown displayed a redistribution of DVL2 to 1 structures that appear to be projections (FIG 6A, right panel) . Quantification of the cellular 2 distribution of DVL2 in the presence and absence of USP9X reveals a significant increase in 3 DVL2 in cellular projections upon loss of USP9X (FIG 6B) . Taken together, our findings indicate 4 that interactions between USP9X and WWP1/NEDD4L regulate a ubiquitin switch on DVL2 that 5 biases its interaction with either the clathrin adaptor AP-2 complex, which is critical for the 6 canonical WNT signaling pathway, or the VANGL1/cofilin complex, which is critical for the non-7 canonical WNT-PCP pathway (FIG 6C) .
Discussion 1
Dishevelled has long been known to play a key role in the transduction of WNT receptor 2
signaling, yet how it is regulated to specify participation in either canonical or non-canonical 3 signaling relays is not well understood. Here, we report that NEDD4 family E3 ubiquitin ligases 4 and their interaction with the deubiquitylase USP9X regulate DVL2 ubiquitylation, and that the 5 deubiquitylation of DVL2 by USP9X is critical for canonical WNT activation. Importantly, we find 6 that USP9X and WWP1 mediate a ubiquitin switch on DVL2 that determines whether DVL2 will 7 preferentially interact with AP-2, a canonical signaling factor, or VANGL1 and cofilin which are 8 critical for the WNT-PCP pathway. Thus, the USP9X-WWP1 axis biases DVL2 participation in 9 either the canonical WNT pathway or the noncanonical WNT-PCP pathway. 10
A Novel Regulatory Axis in the WNT Pathway 11
DVL2 has been reported to undergo both positive and negative regulation by the 12 ubiquitin system through the action of multiple different proteins. For example, both ITCH and 13 NEDD4L have been shown to negatively regulate DVL2 stability by conjugating K48-linked 14 polyubiquitin chains on DVL2, targeting it to the proteasome for degradation (Ding et al., 2013; 15 Liu et al., 2014; Marikawa and Elinson, 1998; Mukai et al., 2010; Tauriello et al., 2010; Wei et 16 al., 2012) . On the other hand, K63-linked polyubiquitin modifications of the DVL2 DIX domain 17 were reported to enhance canonical WNT activation (Tauriello et al., 2010) . The apparent 18 regulation of DVL2 by multiple members of the NEDD4 family could result from functional 19 redundancy, but could also reflect differential regulation based on expression in different 20 contexts or different cell types. Our finding that siRNA targeting of NEDD4L or WWP1 partially 21 rescued WNT activation in the absence of USP9X is consistent with a redundancy model, but it 22 does not exclude the possibility that USP9X antagonizes multiple exclusive ubiquitylation events 23 on DVL2 mediated by different E3 ubiquitin ligases. Indeed, our data suggests that functional 24 regulation of DVL2 by USP9X may involve reversal of multiple distinct ubiquitylation events possibly mediated by multiple E3 ubiquitin ligases -since no single K→R mutation was capable 1 of suppressing the loss of WNT activation phenotype observed in the absence of USP9X (FIG  2   S2) . Additional biochemical and genetic studies will be required to fully understand how USP9X 3 affects various distinct ubiquitylation events on DVL2 that may be mediated by different E3 4 ubiquitin ligases. 5
Previous studies have reported conflicting roles for USP9X with respect to WNT 6 activation. Specifically, USP9X has previously been reported to positively regulate the stability 7 of β-catenin in glioma cells (Yang et al., 2016) . However, USP9X was also reported to 8 negatively regulate the stability of β-catenin in mouse neural progenitor cells (Premarathne et 9 al., 2017) . Our studies are consistent with a positive role for USP9X in canonical WNT pathway 10 activation and a negative role for USP9X in non-canonical WNT-PCP pathway activation. To 11 determine where USP9X functions relative to the β-catenin destruction complex we performed 12 an experiment to test the USP9X requirement for LiCl-mediated activation of the canonical WNT 13 pathway suggesting that USP9X functions upstream of the destruction complex. Although our 14 findings are consistent with a role for USP9X in the regulation of WNT at the level of DVL2 we 15 cannot exclude the possibility of a context-dependent role for USP9X at other tiers of the WNT 16 pathway. Furthermore, it is possible that expression of different NEDD4 family members, other 17 USP9X-interactors, or substrate adaptors and targeting factors could modify USP9X function in 18 a context-specific manner. 19
USP9X and Cancer Biology 20
Given that USP9X has been implicated in the regulation of multiple receptor signaling 21 and trafficking pathways, it is not surprising that in recent years USP9X dysregulation has been 22 linked to many different types of cancers. USP9X has been suggested to exhibit oncogenic 23 behavior in some cancer contexts including multiple myeloma, melanoma, lung cancer, andbreast cancer (Kushwaha et al., 2015; Li et al., 2017; Potu et al., 2017; Schwickart et al., 2010) . 1
In contrast, USP9X has also been proposed to have tumor suppressor activity in other cancers 2 including pancreatic ductal adenocarcinoma (Pérez-Mancera et al., 2012) and colorectal 3 adenocarcinoma (Khan et al., 2018) . Recently, USP9X has been shown to be required for the 4 attenuation of EGFR signaling (Savio et al., 2016) which is suggestive of a tumor suppressor 5 function. Taken together, these reports suggest a complex role for USP9X in cancer 6 progression that may be highly context-dependent. Our findings suggest that USP9X functions 7 along with WWP1 and NEDD4L to regulate a ubiquitylation-deubiquitylation cycle of DVL2. The 8 ubiquitylation status of DVL2 determines its engagement with either canonical or non-canonical 9 WNT factors. Based on these findings we hypothesize that in some cellular contexts increased 10 levels of USP9X may sensitize cells to activation of the canonical WNT pathway (FIG 2E) , which 11 promotes proliferation and tumor growth, while simultaneously antagonizing the non-canonical 12 WNT-PCP pathway which is involved in cell motility and metastasis. These results indicate that 13 dysregulation of USP9X can simultaneously function to promote canonical WNT-driven 14 proliferation while simultaneously guarding against migration and metastasis mediated by the 15 WNT-PCP pathway. Based on these findings, we propose that small molecule inhibitors of 16 USP9X may be effective as antagonists of WNT-based proliferation but they may also ultimately 17 promote migration and metastasis. 18
Regulation of cell signaling pathways by DUB-E3 interactions 19
The ubiquitin proteasome system contributes to the tight spatial and temporal regulation 20 of protein trafficking, localization, and stability. Recently, several examples of interactions 21 between E3 ubiquitin ligases and DUBs have been reported, raising questions about the 22 regulatory significance and design logic of such interactions. In principle, DUB-E3 interactions 23 could facilitate a number of useful design features, including E3 antagonization, E3 24 deubiquitylation, or polyubiquitin chain editing on the substrate. E3 antagonization has thepotential to result in a futile cycle, but coordinated regulation of ligase and DUB activities could 1 also establish a ubiquitin rheostat on a shared substrate. For example, the DUB USP7 interacts 2 with the MAGE-L2-TRIM27 E3 ubiquitin ligase to regulate the ubiquitylation status of WASH, a 3 shared substrate, on the endosome (Wu et al., 2014) . In contrast, E3 deubiqitylation by 4 interacting DUBs could protect the E3 ubiquitin ligase from degradation, stabilizing it and thus 5 promoting its activity. For example, the DUB USP19 promotes cellular proliferation by stabilizing 6 KPC1 (also known as RNF123), a ubiquitin ligase for the cyclin-dependent kinase inhibitor 7 p27Kip1 (also known as CDKN1B) (Lu et al., 2009) . A striking example of polyubiquitin chain 8 editing occurs with the protein A20, a potent inhibitor of the NFkB signaling pathway that 9 contains both a DUB domain and an E3 ubiquitin ligase domain (Wertz et al., 2004) . The DUB 10 domain of A20 removes a K63-linked polyubiquitin chain from the Receptor Interacting Protein 11 (RIP), a protein essential for NFkB signaling, and subsequently, the E3 ubiquitin ligase domain 12 of A20 conjugates a K48-linked polyubiquitin chain to RIP targeting it for degradation by the 13 proteasome -thus inhibiting the NFkB pathway. We have identified a novel E3-DUB interaction 14 that functions to provide layered regulation of the WNT pathway. Our results indicate that the 15 interaction between WWP1 and USP9X plays an important role in the regulation of WNT 16 signaling by incorporating the above-described design features. Functionally, USP9X does 17 seem to antagonize WWP1 and NEDD4L on DVL2 (a shared substrate), and our data also 18 suggests that WWP1 is destabilized in the absence of USP9X (FIG 2D) . Furthermore, our data 19 cannot exclude the possibility that WWP1-USP9x interactions function in a chain-editing 20 capacity on polyubiquitin chains of DVL2. Certainly, it is possible that DUB-E3 interactions 21 facilitate combinations of the above-described design features. Ultimately, rigorous biochemical 22 analysis dissecting mechanisms that regulate and balance of different ubiquitylation and 23 deubiquitylation activities toward DVL2 will be critical to understand its specification in either 24 canonical and noncanonical WNT signaling pathways.
Experimental Procedures 1

Assays for measuring WNT activation 2
Topflash reporter assays in HEK293 STF cells were performed as follows: HEK293 STF 3 cells were seeded on 24-well plates at ~50% confluency. Cells were treated with 100ng/mL 4 purified recombinant WNT3a (R&D Systems) and 100ng/mL purified recombinant R-spondin 5 (R&D systems) 24 hours prior to lysis with 1X Passive Lysis buffer (Promega). Luciferase 6 activity was measured using the Steady-Glo luciferase Assay (Promega). Luciferase signal was 7 normalized to viable cell number using Cell-Titer Glo Assay (Promega). For siRNA knockdown 8 studies, cells were treated for 72 hours prior to lysis, for inhibitor studies cells were treated for 9 24 hours prior to lysis, and for overexpression studies cells were transfected with plasmid DNA 10 for 48 hours prior to lysis. 11
Topflash reporter assays in MDA-MB-231 cells were performed as follows: Cells were 12 plated, co-transfected with TOPflash and Renilla expression plasmids at 24 hours and lysed at 13 48 hours using the Dual-Glo Luciferase Assay system (Promega). Luciferase signal was 14 normalized to co-transfected Renilla expression.Data were normalized to a positive control (set 15 at 100% activation). Assays were performed in triplicate and repeated at least 3 times. 16 Β-catenin stabilization assay: HEK293 STF cells were cultured in Dulbecco's modified 17
Eagle's Medium (DMEM) and activated with WNT3A ligand or LiCl for 24 hours. Then cells were 18 lysed and nuclear/cytoplasmic fractionation was performed as previously described (Thorne et 19 al., 2010) . 20
SILAC-based Quantitative Proteomic Analysis 21
Quantitative mass spectrometry analysis by SILAC was performed on MDA-MB-231 22 cells stably expressing the indicated FLAG-tagged substrates. These cells were cultured in the 23 presence of either heavy or light isotopes (lysine and arginine) for at least 6 doublings to ensure 1 incorporation of these isotopes into 100% of the proteome. Affinity purification was performed as 2 previously described (Lee et al., 2017) . Eluted proteins were digested with 1μg Trypsin Gold 3 (Promega) at 37 F overnight. Digested peptides were cleaned-up on a Sep-Pak C18 column. 4
Purified peptides were then dried, reconstituted in 0.1% trifluoroacetic acid, and analysed by 5 LC-MS/MS using an Orbitrap XL mass spectrometer. Database search and SILAC quantitation 6 were performed using MaxQuant software. 7
Co-Immunoprecipitation Studies 8
For coimmunoprecipitation assays, cells were washed with cold PBS and lysed with a 9 nondenaturing lysis buffer (NDLB): 50mM tris (pH 7.4), 300mM NaCl, 5mM EDTA, 1% Triton X-10 100, cOmplete protease inhibitor cocktail (Roche), Phosphatase inhibitor cocktail (Roche), 1mM 11 PMSF, 1mM Phenanthroline, 10mM Iodoacetamide, and 20μM MG132. Lysates were diluted to 12 1mg/mL with NDLB and incubated with Sigma FLAG EZ-view beads for 2 hours with rotation at 13 4°C. Beads were washed 3 times with cold NDLB and once with cold PBS. Proteins were then 14 eluted from beads using sample buffer and samples were processed for SDS-PAGE followed by 15
immunoblotting. 16
Fluorescence Microscopy 17
MDA-MB-231 cells were seeded on coverslips at 50% confluency. At 24 hours after 18 seeding, cells were transfected with FLAG-Dvl2 using LipoJet Transfection Reagent (Signagen). 19 72 hours after seeding cells were fixed and permeabilized using 4% paraformaldehyde (PFA) 20 and immunofluorescence block buffer (PBS + 0.1% Triton-x + 10% FBS). Cells were then 21 labeled with primary antibodies for 1 hour followed by a 1 hour incubation with alexa-fluor 22 conjugated secondary antibodies. Coverslips were mounted on slides using ProLong AntiFade 23 mountant (Thermo). Microscopy images were acquired using a DeltaVision Elite system (GE 1 Healthcare) and processed using SoftWoRx software (GE Healthcare, Chicago, IL). 2
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